



NETWORK Notification

Notice Date: January 16, 2026
To: Indiana Medicaid Providers
From: CareSource
Subject: Newborn RSV Prevention

Summary

As Respiratory Syncytial Virus (RSV) season approaches, CareSource would like to remind providers of the medications available to prevent severe RSV during the newborn period. RSV continues to be one of the top reasons newborns are hospitalized every year.

Impact

Abrysvo is the only vaccine approved for pregnant people during weeks 32-36 of pregnancy. Beyfortus (Nirsevimab) and Enflonsia are antibodies that can be given one time to infants born during or entering their first RSV season. Vulnerable populations may qualify for a second dose of Beyfortus prior to their second RSV season. Synagis (Palivizumab) is another antibody given multiple times during RSV season to infants more susceptible to severe RSV infections. If a person receives Abrysvo during 32-36 weeks of pregnancy, the newborn will not need the antibody.

Members may receive the medication during an office visit, in the hospital or at a pharmacy.

Requirements for RSV Products:

Indiana Medicaid	Medical Prior Authorization Required	Pharmacy Prior Authorization Required
Abrysvo	No	Must use VFC provider if <19 years old. No PA for \geq 19.
Beyfortus (Nirsevimab)	No	Not Covered
Enflonsia (Clesrovimab)	Covered as specified in bulletin BT2025153; retroactive for dates of service (DOS) on and after July 1, 2025.	Not Covered
Synagis**	Not Covered	PA Required

****Please note: Synagis is discontinued as of December 31, 2025.** Provider must attest to adequate stock in office at time of request to cover member through RSV season.

Importance

Infants at increased risk of severe RSV disease include premature infants, those with chronic lung or heart disease, and who have a weakened immune system. RSV can lead to severe infection like bronchiolitis and pneumonia. Two to three percent of infants with RSV require hospitalization.

Vaccinating pregnant people during the third trimester or providing newborns an antibody injection can play an important role in avoiding severe disease and decreasing hospitalization.

Questions?

If you have any questions or concerns, please contact Health Partner Services at **1-844-607-2831**
Monday through Friday, 8 a.m. to 8 p.m., Eastern Time (ET)/7 a.m. to 7 p.m. Central Time (CT).

IN-MED-P-6578547a; First Use: 01/16/2026

OMPP Approved: 01/12/2026